Company: ABUS
Filing Date: 2025-04-03
Form Type: 8-K
Source: 0001447028-25-000093
Chunk: 1

Company: Arbutus Biopharma Corp
Filing Date: 2025-04-03
Form: 8-K
Item: Item 5.02
Chunk 1
---
 Officer of the Company, effective as of the end of the day on March 27, 2025.

On April 2, 2025, the Company, through the Subsidiary, entered into a Separation Agreement and General Release (the “ Hastings Separation Agreement”) with Mr. Hastings, which sets forth the terms of Mr. Hastings’s separation from the Company, which, other than the following sentence, are materially consistent with his Executive Employment Agreement with the Company, dated as of June 11, 2018 (the “ Hastings Employment Agreement”). In addition to what Mr. Hastings is entitled to pursuant to the terms of the Hastings Employment Agreement, pursuant to the terms of, and subject to compliance with, the Hastings Separation Agreement, the post-termination exercise period of any vested options to purchase common shares of the Company held by Mr. Hastings as of the date of his termination as an employee will be extended for up to a year (March 26, 2026) from the date of such termination. A copy of the Hastings Employment Agreement is filed as Exhibit 10.52 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the U. S. Securities and Exchange Commission on March 7, 2019.

The foregoing description of the Hastings Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the Hastings Separation Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Item 8.01. Other Events.